DUPIXENT® is a biologic treatment for patients aged 6 years and older with moderate-to-severe atopic dermatitis not adequately controlled with topical prescription therapies or when those therapies are not advisable.1

• Injectable biologic
• Recombinant human IgG4 monoclonal antibody1†
• Inhibitor of IL-4 and IL-13 signaling1†
• IL-4 and IL-13 are key Type 2 cytokines involved in atopic disease1

† Clinical significance has not been established.
‡ Clinical significance unknown.

Do these look like your patients?

When topical prescription therapies do not adequately control the disease or are not advisable, consider DUPIXENT® for your appropriate adult patients.1

† Not actual patient. May not be representative of all patients.


Frequently Asked Questions

Have questions? Get answers to some of the most commonly asked questions.

Dosing and Administration

Thinking about prescribing DUPIXENT®? Find helpful information to get started.

Connect With a Rep

Have questions about DUPIXENT®? Get answers from a representative.



DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300298
Last updated: 06/2023

paab logo